Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Zelihagül Değim"'
Publikováno v:
Türk Oftalmoloji Dergisi, Vol 43, Iss 3, Pp 161-166 (2013)
Pur po se: The aim of our study was to investigate the neuroprotective effects of topical α-tocopherol in optic nerve crush model of rat and to compare its efficacy with that of systemic α -tocopherol. Ma te ri al and Met hod: 50 eyes of 25 Wista
Externí odkaz:
https://doaj.org/article/6c09e4d1d6f142a0989fb2b8a2857b3b
Publikováno v:
Drug Delivery with Targeted Nanoparticles ISBN: 9781003164739
Drug Delivery with Targeted Nanoparticles
Drug Delivery with Targeted Nanoparticles
In a dispersion system, colloids interact with one another. It is assumed that these interactions are promoted by two main forces, London-van der Waals forces that lead to attraction and electromagnetic effects that leads to repulsion. The zeta poten
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94a05881c0ec2104950d81250162fad0
https://hdl.handle.net/20.500.12445/2510
https://hdl.handle.net/20.500.12445/2510
Autor:
Özlem Çoban, Zelihagül Değim
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Vol 56 (2020)
Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18583
Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18583
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Brazilian Journal of Pharmaceutical Sciences, Volume: 56, Article number: e18583, Published: 18 SEP 2020
Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18583
Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18583
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Brazilian Journal of Pharmaceutical Sciences, Volume: 56, Article number: e18583, Published: 18 SEP 2020
Imatinib mesylate is a small molecule used in cancer therapy as a thyrosine kinase inhibitor. Dexketoprofen trometamol is a non-steroidal anti-inflammatory drug that has seen use in cancer therapy in combination with an anticancer drug to minimize tu
© 2020 Elsevier B.V.Breast cancer is the most common type of cancer and it is the second common cause of cancer-related deaths in women. Hormonal therapy is a quite well-tolerated treatment, for estrogen receptor (ER) and progesterone receptor-posit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::755b5e3eca20c5ab87aaf2eb1cebe542
https://hdl.handle.net/20.500.12445/1171
https://hdl.handle.net/20.500.12445/1171
Autor:
Firat Yerlikaya, Gamze Camlik, Eduardo Sobarzo-Sánchez, İsmail Tuncer Değim, Zelihagül Değim, Esra Küpeli Akkol
Publikováno v:
Journal of Drug Delivery Science and Technology. 63:102456
The development or designing of new and futuristic drug delivery systems have been mainly focused on nanoparticles and the drug, but the alteration of water properties or configuration of water molecules in these formulations have not been properly a
Publikováno v:
Drug Development Research.
Degim, Zelihagul/0000-0003-2596-3615; ALTINTAS, Levent/0000-0002-5148-723X WOS: 000479314100004 PubMed: 30901500 The main challenges in treating cancer using chemotherapeutics are insufficient dose at the target site and the development of drug resis
Publikováno v:
Turkish Journal of Pharmaceutical Sciences, Vol 13, Iss 1, Pp 69-80 (2016)
Cisplatin is a potent anticancer drug for treating tumors, that has long been widely used. The therapeutic exploitation of cisplatin is limited by its toxicity toward healthy tissues. Liposomes can provide enhanced efficacy and/or reduced toxicity an
Autor:
Özlem Çoban, Zelihagül Değim
Publikováno v:
Turkish Journal of Pharmaceutical Sciences, Vol 15, Iss 1, Pp 16-21 (2018)
Objectives: Erlotinib HCI is a tyrosine kinase receptor inhibitor and an anticancer agent that was first approved by the FDA in 2004 for treatment of non-small-cell lung cancer and pancreatic cancer. Dexketoprofen trometamol is a NSAID, but recent st
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::406db9fe28a50adf91cfe7b5276ea749
https://aperta.ulakbim.gov.tr/record/34767
https://aperta.ulakbim.gov.tr/record/34767
Autor:
Mahmut Sözmen, Şükran Yılmaz, Çiğdem Yücel, Yeşim Aktaş, Taibe Arsoy, Levent Altintas, Zelihagül Değim, Can Çokçalışkan
This work was carried out at the Faculty of Pharmacy of Gazi University as a PhD thesis and supported by the Scientific and Technological Research Council of Turkey (TUBYTAK, No. 112S405).
The present study, aims to investigate and compare the e
The present study, aims to investigate and compare the e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eb6ea39bd33d74955e4b3e22a20d82b
https://hdl.handle.net/20.500.12445/647
https://hdl.handle.net/20.500.12445/647
Autor:
Özlem, Çoban, Zelihagül, Değim
Publikováno v:
Turkish Journal of Pharmaceutical Sciences
Objectives: Erlotinib HCI is a tyrosine kinase receptor inhibitor and an anticancer agent that was first approved by the FDA in 2004 for treatment of non-small-cell lung cancer and pancreatic cancer. Dexketoprofen trometamol is a NSAID, but recent st